Cargando…

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer

BACKGROUND: Microtubule-associated proteins (MAPs) have been considered to play significant roles in the tumor evolution of non-small cell lung cancer (NSCLC). Nevertheless, mRNA transcription levels and prognostic value of distinct MAPs in patients with NSCLC remain to be clarified. METHODS: In thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jieyan, Hu, Qipeng, Gou, Maling, Liu, Xiaoke, Qin, Yi, Zhu, Jiao, Cai, Chengzhi, Tian, Tian, Tu, Zegui, Du, Yijia, Deng, Hongxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517487/ https://www.ncbi.nlm.nih.gov/pubmed/34660263 http://dx.doi.org/10.3389/fonc.2021.680402

Ejemplares similares

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
por: Yu, Yang, et al.
Publicado: (2022)

An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
por: Tu, Zegui, et al.
Publicado: (2023)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
por: Hu, Jian, et al.
Publicado: (2021)

Low Pretreatment Albumin-to-Globulin Ratio Predicts Poor Prognosis in Gastric Cancer: Insight From a Meta-Analysis
por: Wei, Chengzhi, et al.
Publicado: (2021)

Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer
por: Tu, Zegui, et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer
por: Tu, Zegui, et al.
Publicado: (2021)

Lipid Droplet-Related PLIN2 in CD68(+) Tumor-Associated Macrophage of Oral Squamous Cell Carcinoma: Implications for Cancer Prognosis and Immunotherapy
por: He, Yijia, et al.
Publicado: (2022)

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma
por: Zhang, Yu, et al.
Publicado: (2022)

Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer
por: Huang, Youqun, et al.
Publicado: (2023)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Mechanisms of Cancer Resistance to Immunotherapy
por: Bai, Rilan, et al.
Publicado: (2020)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

The value of metabolic LncRNAs in predicting prognosis and immunotherapy efficacy of gastric cancer
por: Du, Peizhun, et al.
Publicado: (2023)

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
por: Wu, Gujie, et al.
Publicado: (2023)

A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma
por: Liu, Hongxiang, et al.
Publicado: (2023)

N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer
por: Zhang, Yuying, et al.
Publicado: (2021)

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
por: Shi, Xiaoxi, et al.
Publicado: (2021)

Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients
por: Zhu, Yankun, et al.
Publicado: (2023)

Identification of a novel necroptosis-related classifier to predict prognosis and guide immunotherapy in breast invasive carcinoma
por: Zhou, Qin, et al.
Publicado: (2022)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
por: Lin, Xinqing, et al.
Publicado: (2021)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers
por: Cai, Yuan, et al.
Publicado: (2022)

Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?
por: Chiruvella, Varsha, et al.
Publicado: (2022)

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
por: Yang, Hongjian, et al.
Publicado: (2023)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2021)

Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy
por: Zhang, Si-yuan, et al.
Publicado: (2021)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

Immunomodulatory Effect of Irreversible Electroporation Alone and Its Cooperating With Immunotherapy in Pancreatic Cancer
por: Tian, Guo, et al.
Publicado: (2021)

An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in kidney renal clear cell carcinoma
por: Wang, Licheng, et al.
Publicado: (2023)

The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

m(6)A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

Identification of gene signatures related to hypoxia and angiogenesis in pancreatic cancer to aid immunotherapy and prognosis
por: Li, Xiushen, et al.
Publicado: (2023)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gre6v44gvgkdscb4rnp14ctpg9